Cargando…

Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth

A recent study of plasma neutralization breadth in HIV-1 infected individuals at nine International AIDS Vaccine Initiative (IAVI) sites reported that viral load, HLA-A*03 genotype, and subtype C infection were strongly associated with the development of neutralization breadth. Here, we refine the f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, S. Abigail, Burton, Samantha L., Kilembe, William, Lakhi, Shabir, Karita, Etienne, Price, Matt, Allen, Susan, Hunter, Eric, Derdeyn, Cynthia A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112890/ https://www.ncbi.nlm.nih.gov/pubmed/27851829 http://dx.doi.org/10.1371/journal.ppat.1005989

Ejemplares similares

VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120
por: Smith, S. Abigail, et al.
Publicado: (2019)

Effect of Glycosylation on an Immunodominant Region in the V1V2 Variable Domain of the HIV-1 Envelope gp120 Protein
por: Tian, Jianhui, et al.
Publicado: (2016)

A neutralizing antibody target in early HIV-1 infection was recapitulated in rhesus macaques immunized with the transmitted/founder envelope sequence
por: Welbourn, Sarah, et al.
Publicado: (2022)

A sequestered fusion peptide in the structure of an HIV-1 transmitted founder envelope trimer
por: Ananthaswamy, Neeti, et al.
Publicado: (2019)

Evolution and diversification of the nuclear envelope
por: Padilla-Mejia, Norma E., et al.
Publicado: (2021)

Hyper-replicative bovine leukemia virus by mutation of an envelope N-linked glycosylation site
por: de Brogniez, A, et al.
Publicado: (2014)

Differentiating founder and chronic HIV envelope sequences
por: Murray, John M., et al.
Publicado: (2017)

Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes
por: O’Brien, Sean P., et al.
Publicado: (2019)

Conformational flexibility of HIV-1 envelope glycoproteins modulates transmitted / founder sensitivity to broadly neutralizing antibodies
por: Ratnapriya, Sneha, et al.
Publicado: (2023)

Signal peptide of HIV-1 envelope modulates glycosylation impacting exposure of V1V2 and other epitopes
por: Upadhyay, Chitra, et al.
Publicado: (2020)

HIV-1 Envelope Glycoprotein Amino Acids Signatures Associated with Clade B Transmitted/Founder and Recent Viruses
por: Kafando, Alexis, et al.
Publicado: (2019)

Solution of K-V envelope equations
por: Anderson, O A
Publicado: (1995)

Exploitation of glycosylation in enveloped virus pathobiology
por: Watanabe, Yasunori, et al.
Publicado: (2019)

Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth
por: Wagh, Kshitij, et al.
Publicado: (2018)

Decay of enveloped SARS-CoV-2 and non-enveloped PMMoV RNA in raw sewage from university dormitories
por: Li, Ye, et al.
Publicado: (2023)

Vaccine-elicited systemic and mucosal humoral responses of lactating rhesus monkeys vaccinated with the transmitted/founder HIV Envelope 1086C
por: Fouda, G, et al.
Publicado: (2012)

Anti-gp41 antibodies inhibit infection and transcytosis of HIV-1 infectious molecular clones expressing transmitted/founder envelopes
por: Jain, S, et al.
Publicado: (2012)

Transmitted/Founder Simian Immunodeficiency Virus Envelope Sequences in Vesicular Stomatitis and Semliki Forest Virus Vector Immunized Rhesus Macaques
por: Gambhira, Ratish, et al.
Publicado: (2014)

Heterologous neutralization breadth persists despite B-lymphocyte dysfunction in chronic HIV-1 infection
por: Murphy, MK, et al.
Publicado: (2012)

HIV-1 Envelope Glycosylation and the Signal Peptide
por: Lambert, Gregory S., et al.
Publicado: (2021)

Significantly Longer Envelope V2 Loops Are Characteristic of Heterosexually Transmitted Subtype B HIV-1 in Trinidad
por: Collins-Fairclough, Aneisha M., et al.
Publicado: (2011)

HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth
por: Fries, Chelsea N., et al.
Publicado: (2021)

Partial HIV C2V3 envelope sequence analysis reveals association of coreceptor tropism, envelope glycosylation and viral genotypic variability among Kenyan patients on HAART
por: Kitawi, Rose C., et al.
Publicado: (2017)

Evolution of Antibody Responses in HIV-1 CRF01_AE Acute Infection: Founder Envelope V1V2 Impacts the Timing and Magnitude of Autologous Neutralizing Antibodies
por: Kuriakose Gift, Syna, et al.
Publicado: (2023)

High throughput analysis of B cell dynamics and neutralizing antibody development during immunization with a novel clade C HIV-1 envelope
por: Mopuri, Rohini, et al.
Publicado: (2023)

Mutational insights into the envelope protein of SARS-CoV-2
por: Rahman, M. Shaminur, et al.
Publicado: (2021)

Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines
por: Zhu, Yufang, et al.
Publicado: (2022)

Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site
por: Cheng, Hao D., et al.
Publicado: (2018)

Arginine insertion and loss of N-linked glycosylation site in HIV-1 envelope V3 region confer CXCR4-tropism
por: Tsuchiya, Kiyoto, et al.
Publicado: (2013)

Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope
por: Barnes, Christopher O., et al.
Publicado: (2018)

Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens
por: Crooks, Emma T., et al.
Publicado: (2021)

Improved Solution of K-v Envelope Equations for Transport in quadrupole channels
por: Anderson, O A
Publicado: (1996)

SARS-CoV-2 envelope protein topology in eukaryotic membranes
por: Duart, Gerard, et al.
Publicado: (2020)

V2 hotspot optimized MVA vaccine expressing stabilized HIV-1 Clade C envelope Gp140 delays acquisition of heterologous Clade C Tier 2 challenges in Mamu-A*01 negative Rhesus Macaques
por: Styles, Tiffany M., et al.
Publicado: (2022)

HIV-1 infections with multiple founders associate with the development of neutralization breadth
por: Lewitus, Eric, et al.
Publicado: (2022)

Posttranslational N-glycosylation of the hepatitis B virus large envelope protein
por: Lambert, Carsten, et al.
Publicado: (2007)

The Patterns of Coevolution in Clade B HIV Envelope's N-Glycosylation Sites
por: Garimalla, Swetha, et al.
Publicado: (2015)

Global site-specific N-glycosylation analysis of HIV envelope glycoprotein
por: Cao, Liwei, et al.
Publicado: (2017)

Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers
por: Bontjer, Ilja, et al.
Publicado: (2013)

Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies
por: Wang, Haoqing, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_p20k24or8n6f4jg1slaer27j4e